Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

In 2022, there were an estimated 2.48 million new cases of trachea, bronchus, and lung cancer worldwide. Breast cancer was the second most common cancer type at that time with around 2.3 million new cases worldwide.

Number of new cancer cases

Cancer can be caused by internal factors like genetics and mutations, as well as external factors such as smoking and radiation. It occurs in the presence of uncontrolled growth and spread of abnormal cells. However, many cancer cases could be prevented, for example, by omitting cigarette usage and heavy alcohol consumption. Risk of developing cancer tends to increase with age and is most common in older adults. Nevertheless, cancer can develop in individuals of any age. Cancer can be treated through surgery, radiation, and chemotherapy, among other methods.

In the United States, there will be an estimated two million new cancer cases and 611,720 deaths in 2024. Among U.S. men, prostate cancer and lung and bronchus cancers are the most common cancer types as of 2024, totaling an estimated 299,010 and 116,310 cases, respectively. In women, breast cancer and lung and bronchus cancer are the most common newly diagnosed types, totaling 310,720 and 118,270 cases, respectively.

According to Cognitive Market Research, the global Cancer Diagnosis market size will be USD 109614.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 32884.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The consumables category is the fastest growing segment of the Cancer Diagnosis industry

Market Dynamics of Cancer Diagnosis Market

Key Drivers for Cancer Diagnosis Market

Increasing Rate of Cancer Diagnostics to Boost Market Growth

The rising global incidence of cancer, which affects millions of people a year, is a primary driver of the need for diagnostic testing. Numerous factors contribute to this tendency, such as the aging population, which increases the risk of developing some cancers in older adults. Changes in lifestyle, including poor eating habits, inactivity, and increased use of alcohol and tobacco, have also contributed to an increase in cancer incidence. Environmental factors, such as exposure to chemicals and hazardous compounds, exacerbate the problem and increase the risk of developing cancer. Therefore, as early detection and diagnosis are becoming more and more important to patients and healthcare professionals, effective cancer diagnostics are essential. The market for cancer diagnostics is expanding as a result of the increased emphasis on prompt and precise cancer detection, which highlights the value of novel diagnostic procedures. For Instance, in 2023, the Pan American Health Organization (PAHO) projects that there will be 20 million new cases and 10 million deaths, and by 2040, nearly 30 million cases will be reported annually.

Innovations in Diagnostic Technologies to Drive Market Growth

The market for cancer diagnostics is expanding as a result of advancements in diagnostic technologies that have greatly improved the precision and effectiveness of cancer detection. For example, non-invasive cancer biomarker identification in physiological fluids is made possible by liquid biopsies, which offer vital insights into tumor dynamics and therapy response. In a similar vein, molecular diagnostics has transformed the detection of particular genetic abnormalities and changes linked to different types of cancer, allowing for more individualized treatment strategies. High-resolution images of tumors are provided by advanced imaging methods like MRI and PET scans, which help with accurate staging and localization. Better patient outcomes result from these technical developments because they increase overall diagnosis accuracy and enable early intervention. The ongoing development of these cutting-edge diagnostic instruments is propelling market expansion and revolutionizing cancer treatment.

Restraint Factor for the Cancer Diagnosis Market

The High Price of Cutting-Edge Diagnostic Technology Will Limit Market Growth

The market for cancer diagnostics is severely hampered by the high price of sophisticated diagnostic tools. Advanced diagnostic instruments, such as molecular tests and imaging technologies, are frequently expensive, which limits healthcare facilities' access to them, especially in settings with limited resources. These institutions' capacity to provide thorough cancer screening and diagnostic services is restricted by this financial barrier, which eventually affects patient outcomes. These financial difficulties are further exacerbated by the costs associated with the development, research, and regulatory approval of new diagnostic instruments. Companies have to spend a lot of money to comply ...

In 2022, there were over 9.7 million cancer deaths worldwide. It is projected that the number of deaths due to cancer worldwide will increase to almost 18.5 million by 2050. The most prevalent type of cancer in 2022 was breast cancer with around 48 prevalent cases per 100,000 population. However, lung cancer is by far the deadliest type of cancer.

Lung Cancer Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. In 2022, around 1.82 million cancer deaths, or 19 percent of all cancer deaths worldwide were attributed to lung cancer. Long-term smoking is known to be a major cause of lung cancer. People who never quit smoking are 24 percent more likely to die before age 65 than people who never smoked in their lives.

Treatment In 2023, it was estimated that there were around 4,492 cancer immunotherapy products in R&D phases, as well as another 3,622 other cancer products in the R&D product pipeline. In the same year, it was projected that there were 965 active drugs for breast cancer, as well as 925 active drugs for non-small cell lung cancer.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

It is estimated that around 280,000 new cases of cancer will be diagnosed in Spain during 2023, of which 160,000 are expected in men and 120,000 in women. Breast cancer is expected to be the type with the highest incidence in the country, with more than 35,000 new cases estimated for 2023, followed by lung and prostate cancer with 31,282 and 29,002 cases, respectively.

Cancer-related deaths

In 2021, cancer was responsible for approximately 114,000 deaths in Spain. Lung and bronchial cancer caused the highest number of cancer deaths in the country, accounting for approximately 22,400 terminal cases. In fact, it was the fourth main cause of death overall, only after COVID-19, coronary artery disease (CAD), and cerebrovascular disease. Lung cancer is highly associated with smoking and is therefore among the most preventable diseases.

Most common types of cancer worldwide

Breast cancer is the most common type of cancer among women in the world. In 2020, around a quarter of all new cancer cases within this group was attributed to breast cancer. Colorectum and lung cancer followed, accounting for 9.4 and 8.4 percent of all new cancer cases among women that year, respectively. In comparison, lung cancer was the most common type of cancer among men, with a share of 14.3 percent. Prostate cancer followed closely, with 14.1 percent.

Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is forecast to increase by USD 121.9 million, at a CAGR of 14% between 2024 and 2029.

The market is witnessing significant growth due to the escalating prevalence of cancer cases worldwide. The increasing incidence of various types of cancer necessitates the implementation of advanced registry software solutions to manage and analyze patient data more efficiently. Moreover, the burgeoning clinical research in oncology further drives the demand for these systems, as they facilitate data collection, management, and analysis for research purposes. However, the market faces challenges in the form of stringent data privacy and security concerns. With the growing amount of sensitive patient information being stored and shared digitally, ensuring robust data security becomes crucial. The potential risks of data breaches and unauthorized access can significantly impact both patients and healthcare providers, necessitating the adoption of advanced security measures. Companies in the market must prioritize data security and privacy to gain the trust of healthcare organizations and patients alike.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market is a dynamic and evolving landscape, continually adapting to advancements in healthcare technology and the growing demand for comprehensive cancer data management. This market encompasses various applications, including disease registry management, cancer staging system, data warehousing, cancer incidence tracking, registry software architecture, data integration platform, clinical data capture, case reporting system, statistical reporting, cancer screening programs, and more. These tools play a crucial role in cancer surveillance systems, enabling the collection, analysis, and reporting of epidemiological data for public health surveillance. They facilitate data encryption for patient data privacy, ensuring HIPAA compliance. Data interoperability and data quality metrics are essential components, allowing for seamless integration of various health informatics tools. Real-time data updates and database management systems are integral to maintaining accurate and up-to-date information. Predictive modeling tools and data mining techniques contribute to risk factor identification and mortality data analysis. Data visualization tools offer valuable insights into the complexities of cancer data. Cancer registry software architecture supports population-based registry initiatives, ensuring secure data storage and registry reporting features. Oncology data management tools enable clinical data capture, case reporting, and statistical reporting, enhancing overall patient care. The ongoing development and refinement of these tools reflect the continuous unfolding of market activities and evolving patterns in cancer data management.

How is this Cancer Registry Software Industry segmented?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. End-userGovernment and third partyPharma biotech and medical device companiesHospitals and medical practicePrivate payersResearch institutesTypeStand-alone softwareIntegrated softwareDeploymentOn-premisesCloud-basedGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyItalySpainUKAPACChinaJapanRest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.Cancer registry software solutions play a vital role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These systems enable the tracking of cancer incidence, prevalence, and mortality rates, providing essential information for public health planning, resource allocation, and policy development. Analyzing trends and patterns in registry data helps identify high-risk populations, geographic disparities, and emerging cancer types. Governments utilize cancer registry software to monitor and improve the quality of cancer care. By evaluating variations in treatment practices and adherence to clinical guidelines, they can benchmark outcomes against national or international standards. Additionally, these software solutions facilitate data interoperability, ensuring data quality metrics and HIPAA compliance. Data encryption, data visualization tools, and predictive modeling capabilities enhance the functionality of cancer registry software. Epidemiological data analysis and risk factor identificatio

Global Breast Cancer Screening (Programme Data) by Country, 2023 Discover more data with ReportLinker!

The Global Cancer Registry Software Market size was valued at USD 56.1 million in 2023 and is projected to reach USD 112.85 million by 2032, exhibiting a CAGR of 10.5 % during the forecasts period. Global Cancer Registry Software relates to the much-needed software systems for accumulating and processing cancer patients’ data in various centres. These software platforms allow clinics, hospitals and research institutions to monitor cases of cancer and other diseases to develop or to investigate epidemiological trends and clinical effectiveness. They are a central player in cancer screening, early detection prevention plans and evaluation of trends in the provision of health care services and community health. Examples of using the system are working with cancer cases, preparing reports to authorized bodies, follow up of the patients, and other interprofessional cooperation in research. It is incumbent to note that the current trends embrace the application of artificial intelligence in analyzing big data, use of cloud computing solutions, and a growing concern on the ability of the registries to interoperate as providers of health care information around the globe. The market development is based on the growing rates of cancer diseases globally, and the need to enhance the outcomes of cancer care by using advanced data management systems.

Cancer Immunotherapy Market size was valued at USD 121696.34 Million in 2023 and is expected to reach USD 310458.68 Million in 2031, at a CAGR of 13.70% over the forecast period of 2024 to 2031.

Key Market Drivers • Rising Global Cancer Burden: The escalating incidence of cancer worldwide is a primary driver for the Cancer Immunotherapy Market. According to the WHO's GLOBOCAN 2022 database, approximately 19.3 million new cancer cases were reported in 2020, with this number projected to reach 28.4 million by 2040. The American Cancer Society reported that immunotherapy treatments were recommended for approximately 42% of all newly diagnosed cancer patients in 2023, up from 28% in 2020. • Improving Treatment Success Rates: Enhanced efficacy of immunotherapy treatments is driving market growth. The FDA reported that the response rate for checkpoint inhibitor immunotherapies increased from 26.5% in 2020 to 41.3% in 2023 across various cancer types. The American Society of Clinical Oncology (ASCO) documented that CAR T-cell therapy showed complete remission rates of 83% in specific blood cancers by 2023, compared to 67% in 2020.

Cancer Registry Software Market Outlook

In 2023, the global cancer registry software market size was estimated to be approximately USD 100 million, and it is projected to reach around USD 172 million by 2032, growing at a compound annual growth rate (CAGR) of 6.5%. The increasing prevalence of cancer worldwide is a significant growth factor for this market. As the burden of cancer continues to rise, the demand for effective data management systems through cancer registry software is also escalating. These systems aid in the comprehensive collection, storage, analysis, and interpretation of cancer data, which is crucial for better understanding and managing the disease across various healthcare settings.

One of the primary growth factors driving the cancer registry software market is the increasing emphasis on cancer surveillance systems. Governments and healthcare organizations worldwide are prioritizing the development and implementation of robust cancer registries to improve cancer control and prevention strategies. This trend is particularly prevalent in regions with high cancer incidence rates, where the need for accurate and reliable data collection is critical. Furthermore, technological advancements in data management and interoperability are enhancing the capabilities of cancer registry software, making them more efficient and user-friendly, thereby boosting their adoption across various healthcare facilities.

Additionally, the integration of cancer registry software with other healthcare information systems is becoming increasingly important. As healthcare providers strive to create a more interconnected and holistic view of patient care, the need for seamless integration between cancer registries and electronic health record systems is growing. This integration facilitates better data sharing and communication among healthcare professionals, ultimately leading to improved patient outcomes. Moreover, the transition towards value-based care models in healthcare is further driving the demand for cancer registry software, as these systems enable providers to track and report on quality measures and patient outcomes more effectively.

The rising awareness and education about cancer prevention and early detection are also contributing to the growth of the cancer registry software market. Public health initiatives and campaigns aimed at increasing awareness about cancer symptoms and screening options are encouraging more individuals to seek medical attention, leading to earlier diagnoses and treatment. Consequently, the need for comprehensive cancer data collection and analysis is increasing, further driving the demand for cancer registry software. Furthermore, collaborations between government bodies, non-profit organizations, and private entities to improve cancer data management and dissemination are expected to provide additional impetus to the market's growth.

From a regional perspective, North America currently holds the largest share of the cancer registry software market, attributed to the advanced healthcare infrastructure, high awareness levels, and significant government investments in cancer research and surveillance programs. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by the increasing incidence of cancer, improving healthcare infrastructure, and growing government initiatives to enhance cancer data management. The rapid adoption of cloud-based solutions and advancements in healthcare IT are further propelling market growth in this region, as they offer scalable and cost-effective options for managing large volumes of cancer data.

Type Analysis

Within the cancer registry software market, the type segment is divided into standalone software and integrated software. Standalone software refers to systems that function independently without the need for integration with other healthcare information systems. These solutions are often preferred by smaller healthcare facilities or entities with limited IT infrastructure, as they are typically easier to implement and require less technical expertise. Despite their simplicity, standalone systems provide essential functionalities for managing cancer registries, including data entry, storage, and basic reporting features. However, the limited scalability and interoperability of standalone software can pose challenges for larger organizations with more complex data needs.

In contrast, integrated software solutions are designed to work in conjunction with other healthcare information systems, such as electronic health records (EHRs) or labor

Introduction

The Cancer Registry Software Market is projected to grow significantly, reaching a value of USD 205.7 million by 2033 from USD 78.6 million in 2023. This growth, driven by a compound annual growth rate (CAGR) of 10.1%, is attributed to the increasing global cancer incidence and rising demand for data management solutions in healthcare organizations. As cancer becomes a leading cause of death worldwide, healthcare providers are increasingly adopting cancer registry software to improve case tracking, surveillance, and treatment outcomes. The market is further supported by government initiatives aimed at enhancing national cancer registries.

Government regulations and national cancer registry programs are crucial drivers of this market's growth. Several countries are investing in enhancing their cancer surveillance systems to improve early detection and treatment outcomes. For instance, the U.S. Centers for Disease Control and Prevention (CDC) provides funding to support cancer registries. These initiatives not only encourage software adoption but also ensure adherence to state and federal reporting standards. As cancer data collection and analysis become a priority, cancer registry software is becoming indispensable to healthcare providers.

Technological advancements in Artificial Intelligence (AI) and Machine Learning (ML) are another key factor contributing to the market’s growth. The integration of these technologies into cancer registry software enables more efficient data collection, analysis, and reporting. AI and ML help identify trends, predict future cancer burdens, and support personalized treatment strategies. As these technologies evolve, their continued integration into registry software will drive further expansion, allowing healthcare professionals to make more informed decisions based on reliable data.

The growing need for real-time data for clinical decision-making and research is also fueling market growth. Cancer registry software plays a pivotal role in providing healthcare professionals with up-to-date information, crucial for both patient care and clinical research. Real-time cancer data is used to develop new therapies and improve treatment strategies. Researchers are increasingly relying on these databases to expedite breakthroughs in cancer treatment, which is contributing to the adoption of registry software solutions.

In summary, the Cancer Registry Software Market is experiencing rapid growth due to multiple factors, including the rising global cancer prevalence, government support, technological advancements, and the increasing demand for real-time cancer data. These elements are expected to continue driving market expansion as healthcare providers and governments prioritize cancer surveillance and management. The growing awareness of cancer's impact and the need for efficient data management are pivotal in sustaining the growth of this sector.

The global cancer profiling market is experiencing robust growth, driven by the increasing prevalence of cancer, advancements in diagnostic technologies, and a rising demand for personalized medicine. The market's Compound Annual Growth Rate (CAGR) of 10.80% from 2019 to 2024 indicates a significant expansion, and this upward trajectory is expected to continue throughout the forecast period (2025-2033). Technological advancements, particularly in next-generation sequencing (NGS) and immunoassays, are significantly contributing to this growth. NGS provides comprehensive genomic profiling, enabling the identification of a wider range of biomarkers for targeted therapies and improved patient outcomes. Immunoassays, while offering a more established and cost-effective approach, remain vital for detecting specific tumor markers. The market is segmented by technology, cancer type, and biomarker type, reflecting the diverse approaches to cancer profiling. Breast, lung, and colorectal cancers currently represent major segments, given their high prevalence and the availability of targeted therapies. However, the market is also expanding to encompass a wider range of cancer types as research continues to uncover relevant biomarkers. The utilization of genetic and protein biomarkers is driving market growth, leading to the development of more precise diagnostic and therapeutic strategies. While the market faces certain restraints, including high testing costs and regulatory hurdles, the overall outlook remains positive, driven by continued technological innovation and increased investment in cancer research. The geographical distribution of the cancer profiling market reflects global healthcare spending patterns and cancer incidence rates. North America currently dominates the market, primarily due to advanced healthcare infrastructure, high adoption rates of innovative technologies, and substantial research funding. Europe holds a significant share, driven by robust healthcare systems and increasing focus on personalized oncology. The Asia-Pacific region is expected to witness substantial growth in the coming years, propelled by rising cancer prevalence, increasing healthcare expenditure, and growing awareness of advanced diagnostic techniques. Emerging economies within this region present significant opportunities for market expansion. Companies involved in the cancer profiling market are actively engaged in developing advanced technologies, expanding their product portfolios, and forming strategic partnerships to strengthen their market positions. The competitive landscape is characterized by a mix of established players and emerging companies vying for market dominance. Recent developments include: May 2023: Pfizer and Thermo Fisher Scientific Inc. entered a strategic partnership agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across the globe., March 2023: Point32Health and Foundation Medicine, a company in molecular profiling for cancer, entered into a partnership to make FoundationOne CDx and FoundationOne Liquid CDx comprehensive genomic profiling (CGP) tests available to Point32Health members with advanced cancer, including Medicaid members.. Key drivers for this market are: Increasing Incidence of Cancer, Increasing Cancer Research and Funding. Potential restraints include: Increasing Incidence of Cancer, Increasing Cancer Research and Funding. Notable trends are: Colorectal Cancer is Expected to Hold a Significant Market Share Over the Forecast Period.

Cancer Tissue Diagnostics Market size was valued at USD 56.71 Billion in 2023 and is projected to reach USD 83.27 Billion by 2030, growing at a CAGR of 9.4% during the forecast period 2024-2030.

Global Cancer Tissue Diagnostics Market Drivers

The growth and development of the Cancer Tissue Diagnostics Market is attributed to certain main market drivers. These factors have a big impact on how Cancer Tissue Diagnostics are demanded and adopted in different sectors. Several of the major market forces are as follows:

Growing Cancer prevalence and Prevalence: One major factor driving the need for cancer tissue diagnostics is the increased prevalence of different types of cancer worldwide. Accurate and timely diagnostic techniques are in more demand as cancer rates rise.

Developments in Diagnostic Technologies: As a result of ongoing improvements in the sensitivity, specificity, and accuracy of cancer tissue diagnostics, the market is expected to grow. Examples of these technologies include immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), and molecular diagnostics.

Rise of Personalized Medicine: By identifying certain biomarkers, genetic mutations, and molecular profiles in tumors, cancer tissue diagnostics contribute significantly to personalized medicine. This helps pick focused therapies, which in turn drives market demand.

Growing Stress on Early Detection: A cancer patient's prognosis depends heavily on early detection. Diagnostics using cancer tissue can identify tumors accurately and early, which improves prognosis and treatment options.

Multi Cancer Screening Market Outlook

The global multi cancer screening market size was valued at approximately $3.5 billion in 2023 and is expected to surge to around $12 billion by 2032, exhibiting a robust CAGR of 15.2% over the forecast period. This remarkable growth is driven primarily by advancements in diagnostic technologies, rising cancer prevalence, and growing awareness about early detection's benefits in improving survival rates. These factors collectively contribute to the market's dynamic expansion, as stakeholders increasingly recognize the value of comprehensive cancer screening solutions.

One of the primary growth factors for the multi cancer screening market is the technological innovation in diagnostic tools. Next-generation sequencing (NGS), polymerase chain reaction (PCR), and advanced imaging techniques have significantly enhanced the accuracy and efficiency of cancer detection. These technologies allow for the simultaneous screening of multiple cancer types, providing a more comprehensive diagnostic approach. The continuous evolution of these technologies promises to further improve detection rates, reduce false positives, and make screenings more accessible and cost-effective.

Another significant contributor to market growth is the increasing awareness and emphasis on early cancer detection. Early diagnosis is crucial for effective treatment and improved survival rates in cancer patients. Governments, healthcare organizations, and non-profit entities are actively promoting early screening programs, leading to a higher adoption rate among the population. Campaigns and educational initiatives highlighting the importance of regular screenings are instrumental in driving market demand.

Breast Cancer Screening Tests have become an integral part of early detection strategies, significantly impacting survival rates. These tests, including mammograms, ultrasounds, and MRIs, are designed to identify breast cancer at its earliest stages, often before symptoms develop. The integration of advanced imaging technologies and genetic testing has further enhanced the accuracy and reliability of these screenings. As awareness grows, more women are participating in regular breast cancer screenings, leading to earlier interventions and improved outcomes. Healthcare providers are increasingly advocating for personalized screening plans based on individual risk factors, ensuring that each patient receives the most appropriate care.

Additionally, the rising global cancer burden is a critical factor propelling the multi cancer screening market. According to the World Health Organization, cancer is one of the leading causes of death worldwide, with millions of new cases diagnosed each year. This alarming increase in cancer incidence underscores the urgent need for effective screening programs. As a result, healthcare systems and providers are investing heavily in multi cancer screening technologies to address this growing health challenge.

Regionally, North America dominates the multi cancer screening market due to its well-established healthcare infrastructure, high healthcare expenditure, and significant investments in research and development. Europe follows closely, with its strong focus on cancer research and public health initiatives. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by improving healthcare facilities, increasing healthcare awareness, and supportive government initiatives in countries like China and India.

Test Type Analysis

The multi cancer screening market is segmented by test type into blood-based, urine-based, tissue-based, and others. The blood-based segment holds the largest market share, primarily due to its non-invasive nature and ease of sample collection. Blood-based tests are preferred for their ability to provide comprehensive insights into multiple cancer types from a single sample. Additionally, these tests are gaining traction due to the advancements in liquid biopsy technologies, which enhance the detection of circulating tumor DNA and other biomarkers.

Urine-based tests are also gaining attention for their non-invasive approach and potential to detect certain cancers at an early stage. These tests are particularly useful for cancers such as bladder and prostate cancer. The convenience and comfort associated with urine sample collection contribute to their increasing adoption. Moreover, ongoing

Snapshot img

Cancer Immunotherapy Market Size 2024-2028

The cancer immunotherapy market size is forecast to increase by USD 45.5 billion at a CAGR of 8.1% between 2023 and 2028. The market is witnessing substantial growth due to the high prevalence of cancer, increasing consumer awareness towards advanced treatment options, and a robust Research and Development (R&D) pipeline focusing on monoclonal antibodies. This expansion is primarily driven by the demand for innovative solutions, advancements in technology, and evolving consumer preferences. As the industry evolves, there is a transition towards more efficient systems, improved accessibility, and higher industry standards. Companies in this sector are adapting their strategies to align with these trends, prioritizing sustainability and operational efficiency to maintain a competitive edge. The market's future direction is influenced by these factors, ensuring long-term growth and expansion. The growing demand for advanced cancer treatment solutions continues to fuel market evolution, with a focus on delivering effective, accessible, and cost-efficient therapies.

What will be the size of the market during the forecast period?

Request Free Sample

Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Type

  Monoclonal antibodies
  Check point inhibitors and immunomodulators
  Cancer vaccines


Application

  Lung cancer
  Breast cancer
  Colorectal cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    France


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

Monoclonal antibodies and checkpoint inhibitors have emerged as key players In the cancer treatment landscape. These man-made proteins, designed to mimic the immune system's response, are used to target specific cancer cells, such as those expressing human epidermal growth factor receptor 2 in breast cancer, treated with trastuzumab. Lung, colorectal, melanoma, breast, head & neck, and prostate cancers are among the many types treated with these agents. Hospitals, clinics, and cancer research centers administer these therapies, which include cancer vaccines, immunomodulators, target therapies, and traditional chemotherapies or radiation therapy. Immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have revolutionized cancer treatment, offering improved patient outcomes.

Financial burden remains a concern, with new treatments like quizartinib for acute myeloid leukemia and FLT3 inhibitors under development. Bioinformatics tools aid In the discovery and development of these therapies. Oncolytic viral therapies, such as talimogene laherparepvec and sipuleucel-T, and repotrectinib, a selective TRK inhibitor, are also gaining popularity. The healthcare industry, including hospital pharmacies and online pharmacies, plays a crucial role In the distribution and administration of these treatments.

Get a glance at the market share of various regions. Download the PDF Sample

The Monoclonal antibodies segment was valued at USD 36.30 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 43% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The North American region leads The market due to substantial investments In the oncology sector, particularly In the US. With a significant presence of pharmaceutical companies, the US dominates the regional market and contributes significantly to its global share. In the US, cancer is a prevalent chronic disease, with approximately 436 new cases reported per 100,000 population and 156 deaths In the same year. Immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and cancer vaccines, are increasingly used for treating various types of cancer, such as lung, breast, colorectal, melanoma, head & neck, prostate, and others. Hospitals, clinics, and cancer research centers are key end-users of these therapies.

Immunomodulators, target therapies, traditional chemotherapies, and radiation therapies are also used in combination with immunotherapies. Financial burden remains a challenge for cancer patients, with treatments like quizartinib for acute myeloid leukemia and FLT3 inhibitors requiring significant inv

Snapshot img

Cancer Biologics Market Size 2025-2029

The cancer biologics market size is forecast to increase by USD 84.5 billion, at a CAGR of 10.7% between 2024 and 2029.

The market is witnessing significant growth due to the rising global incidence of cancer, which continues to be a major health concern worldwide. This trend is fueled by an aging population, unhealthy lifestyles, and environmental factors. The untapped potential of cancer biologics in developing countries presents a substantial opportunity for market expansion. However, the high cost of these advanced therapies poses a significant challenge. As the market evolves, companies must stay abreast of emerging trends, including the increasing use of personalized medicine, the growing importance of immuno-oncology therapies, and the development of cancer vaccines. Additionally, artificial intelligence is playing a key role in accelerating drug discovery, optimizing treatment plans, and improving patient outcomes through data-driven insights.
By addressing these challenges and leveraging the growing demand for cancer biologics, companies can establish a strong presence in this dynamic and evolving market.

What will be the Size of the Cancer Biologics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by the ongoing development of innovative therapies and technologies. Phase III trials for various cancer treatments, including PD-1 and PD-L1 inhibitors, CTLA-4 inhibitors, and BRAF inhibitors, are underway, pushing the boundaries of treatment efficacy. Radiation therapy is being integrated with precision medicine, allowing for more targeted and personalized approaches. Emerging technologies, such as gene therapy, epigenetic modifiers, and CAR-T cell therapy, are reshaping the landscape of cancer treatment. Adverse events remain a significant concern, necessitating rigorous quality assurance and control measures in pharmaceutical and biopharmaceutical manufacturing. Palliative care and adjuvant therapy are gaining importance in cancer treatment, with a focus on improving patient outcomes and quality of life.

Tumor heterogeneity and drug resistance continue to pose challenges, necessitating the development of new diagnostic imaging and drug delivery systems. Healthcare economics and health equity are becoming increasingly relevant in cancer care, with a growing emphasis on affordable and accessible treatments. Regulatory approval processes and intellectual property considerations continue to shape the market dynamics. The evolving nature of cancer biologics requires a robust supply chain management system, ensuring the timely and efficient delivery of these complex therapies. Survival rates remain a critical metric in evaluating the success of new treatments, driving the ongoing research and development efforts.

How is this Cancer Biologics Industry segmented?

The cancer biologics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Monoclonal antibodies
  Cell and gene therapy
  Vaccines
  Others


Route Of Administration

  Injectable
  Oral


Type

  Breast cancer
  Lung cancer
  Colorectal cancer
  Prostate cancer
  Others


Distribution Channel

  Hospitals
  Clinics
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Argentina
    Brazil


  Middle East and Africa

    UAE


  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

Monoclonal antibodies have emerged as a significant therapeutic approach in cancer treatment, inhibiting tumor growth by targeting specific proteins involved in angiogenesis and cell division. These targeted therapies, including monoclonal antibodies, prevent cancer progression and carcinogenesis with minimal side-effects on healthy cells. In the realm of cancer research, various entities are driving innovation. For instance, bispecific antibodies, such as Johnson & Johnson's Talquetamab-tgvs, approved in August 2023 for relapsed or refractory multiple myeloma, engage T-cells and target CD3 and GPRC5D. Small molecule inhibitors and tyrosine kinase inhibitors, like PD-1 inhibitors, are another class of drugs that inhibit tumor growth by blocking specific proteins.

PD-L1 inhibitors, such as Merck's Keytruda, have shown remarkable success in treating various cancers. In addition, immune checkpoint inhibitors, such as Opdivo from Bristol Myers Squi

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

BCC Research Report: Dive into Nanotechnology in Cancer Treatments market report includes global revenue ($ Million) for base year data of 2023 and estimated data for the forecast period 2024 through 2029.